Form 4: Vir Biotechnology EVP Acquires Shares and Grants Power of Attorney

Mark Eisner, EVP and Chief Medical Officer of Vir Biotechnology, acquired 40,000 shares of common stock and granted a power of attorney for SEC filings.

Summary

• Mark Eisner, the EVP and Chief Medical Officer of Vir Biotechnology, acquired 40,000 shares of common stock on February 22, 2025, at a price of $0 per share.
• Following the transaction, Eisner directly owns 115,000 shares of common stock.
• Eisner also acquired a stock option to purchase 80,000 shares of common stock at an exercise price of $9.57, which vests over time starting February 22, 2026.
• Eisner granted a power of attorney to several individuals to execute and file SEC forms on his behalf, effective January 29, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive is generally viewed favorably, suggesting confidence in the company's prospects. The power of attorney is a standard administrative procedure.

Positives

• The acquisition of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the stock options suggests a long-term incentive structure for the executive.

Industry Context

Executive stock ownership and option grants are common practices in the biotechnology industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in the biotechnology industry, often vesting over a period of several years to incentivize long-term performance.
• The size of the grant and vesting schedule are generally comparable to those offered by similar-sized biotech companies to their executive teams.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options and restricted stock units as part of their executive compensation plans.

Stakeholder Impact

• The stock acquisition could have a slightly positive impact on shareholder sentiment.
• The stock option grant incentivizes the executive to work towards increasing shareholder value.

Key Dates